() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

Category Archives: Eve & Co

Eve & Co Announces Financial Results For The Year Ended December 31, 2019

Eve & Co Incorporated (the “Company” or “Eve & Co”) (TSX-V: EVE; OTCQX: EEVVF) is pleased to announce its financial results for the year ended December 31, 2019. The financial statements and management discussion and analysis for such period are available on the System for Electronic Document Analysis and Retrieval ("SEDAR") at www.sedar.com and on Eve & Co's website at www.evecannabis.ca.
Read more

Eve & Co Announces Management Change

Eve & Co Incorporated (“Eve & Co” or the “Company”) (TSX-V: EVE; OTCQX: EEVVF) today announces that Landon Roedding has tendered his resignation as the Company's Chief Financial Officer.
Read more

Eve & Co Announces Exclusive LOI With Dr. Kerklaan Therapeutics

Eve & Co Incorporated (“Eve & Co” or the “Company”) (TSX-V: EVE; OTCQX: EEVVF) is pleased to announce that its wholly-owned subsidiary, Natural MedCo Ltd. (“Natural MedCo”), has entered into an exclusive letter of intent (the “LOI”) with ECS BioMed Inc. (“Dr. Kerklaan Therapeutics”) effective January 14, 2020. The LOI contemplates the exclusive right and license to manufacture, import and export, warehouse, package, advertise, market, distribute and sell the following products in Canada under the Dr. Kerklaan Therapeutics brand, under the Eve & Co brand, or as co-branded products under the Eve &
Read more